The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands

SIMPLE SUMMARY: CAR T-cell therapy has emerged as the new standard of care for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL), but real-world outcomes differ across countries. Additionally, real-world data on health-related quality of life (HR-QoL) are scarce but important, as...

Descripción completa

Detalles Bibliográficos
Autores principales: Spanjaart, Anne M., Pennings, Elise R. A., Mutsaers, Pim G. N. J., van Dorp, Suzanne, Jak, Margot, van Doesum, Jaap A., de Boer, Janneke W., Niezink, Anne G. H., Kos, Milan, Vermaat, Joost S. P., Sijs-Szabo, Aniko, van der Poel, Marjolein W. M., Nijhof, Inger S., Kuipers, Maria T., Chamuleau, Martine E. D., Lugtenburg, Pieternella J., Doorduijn, Jeanette K., Serroukh, Yasmina I. M., Minnema, Monique C., van Meerten, Tom, Kersten, Marie José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486925/
https://www.ncbi.nlm.nih.gov/pubmed/37686611
http://dx.doi.org/10.3390/cancers15174334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486925/
https://www.ncbi.nlm.nih.gov/pubmed/37686611
http://dx.doi.org/10.3390/cancers15174334

Ejemplares similares